Letermovir for Cytomegalovirus Prevention in Adolescent Patients Following Hematopoietic Cell Transplantation

被引：19

作者：

Daukshus, Nicole ^{[1
]}

Cirincione, Anthony ^{[2
]}

Siver, Molly ^{[3
]}

Mathew, Sherry ^{[1
]}

Kunvarjee, Binni ^{[1
]}

Chan, Amelia ^{[1
]}

Boelens, Jaap Jan ^{[4
]}

Seo, Susan K. ^{[5
]}

Papanicolaou, Genovefa A. ^{[5
]}

Kernan, Nancy A. ^{[4
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Pharm, 1275 York Ave, New York, NY 10021 USA

[2] Maine Med Ctr, Dept Pharm, Portland, ME 04102 USA

[3] Hackensack Univ Med Ctr, Dept Pharm, Hackensack, NJ USA

[4] Mem Sloan Kettering Canc Ctr, Stem Cell Transplantat & Cellular Therapies, MSK Kids, 1275 York Ave, New York, NY 10021 USA

[5] Mem Sloan Kettering Canc Ctr, Infect Dis Serv, New York, NY 10021 USA

来源：

JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY | 2022年 / 11卷 / 07期

关键词：

adolescents; cytomegalovirus; hematopoietic cell transplant; letermovir; PROPHYLAXIS; INFECTION;

D O I：

10.1093/jpids/piac017

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

There are limited data for letermovir as primary cytomegalovirus (CMV) prophylaxis in patients less than 18 years of age. We report 9 adolescent patients who received letermovir following hematopoietic cell transplantation. No patients developed clinically significant CMV while taking letermovir. Letermovir was well tolerated and efficacious in preventing CMV infections.

引用

页码：337 / 340

页数：4

共 12 条

[1] Survey of CMV management in pediatric allogeneic HSCT programs, on behalf of the Inborn Errors, Infectious Diseases and Pediatric Diseases Working Parties of EBMT [J].

Bontant, T. ;

Sedlacke, P. ;

Balduzzi, A. ;

Gaspar, B. ;

Cesaro, S. ;

Einsele, H. ;

Peters, C. ;

Dalle, J-H .

BONE MARROW TRANSPLANTATION, 2014, 49 (02) :276-279

[2]

Camacho-Bydume C, 2020, BIOL BLOOD MARROW TR, V26, pS347

[3] Antiviral prophylaxis for cytomegalovirus infection in allogeneic hematopoietic cell transplantation [J].

Chen, Kaiwen ;

Cheng, Matthew P. ;

Hammond, Sarah P. ;

Einsele, Hermann ;

Marty, Francisco M. .

BLOOD ADVANCES, 2018, 2 (16) :2159-2175

[4]

Cho SY., 2019, INT J MOL SCI, V20, P1

[5]

Databases USFDA, PREVYMIS LET TABL PR

[6] How I treat CMV reactivation after allogeneic hematopoietic stem cell transplantation [J].

Einsele, Hermann ;

Ljungman, Per ;

Boeckh, Michael .

BLOOD, 2020, 135 (19) :1619-1629

[7] Cytomegalovirus in Hematopoietic Stem Cell Transplant Recipients [J].

Ljungman, Per ;

Hakki, Morgan ;

Boeckh, Michael .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (01) :151-+

[8] Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell Transplantation [J].

Marty, F. M. ;

Ljungman, P. ;

Chemaly, R. F. ;

Maertens, J. ;

Dadwal, S. S. ;

Duarte, R. F. ;

Haider, S. ;

Ullmann, A. J. ;

Katayama, Y. ;

Brown, J. ;

Mullane, K. M. ;

Boeckh, M. ;

Blumberg, E. A. ;

Einsele, H. ;

Snydman, D. R. ;

Kanda, Y. ;

DiNubile, M. J. ;

Teal, V. L. ;

Wan, H. ;

Murata, Y. ;

Kartsonis, N. A. ;

Leavitt, R. Y. ;

Badshah, C. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25) :2433-2444

[9] Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients [J].

Stern, Lauren ;

Withers, Barbara ;

Avdic, Selmir ;

Gottlieb, David ;

Abendroth, Allison ;

Blyth, Emily ;

Slobedman, Barry .

FRONTIERS IN MICROBIOLOGY, 2019, 10

[10] Letermovir in paediatric HSCT recipients [J].

Strenger, Volker ;

Sperl, Daniela ;

Kubesch, Klaus ;

Donnerer, Josef ;

Schwinger, Wolfgang ;

Zach, Klara ;

Lackner, Herwig ;

Benesch, Martin .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019, 74 (09) :2820-2821

← 1 2 →